Is ELI LILLY & Co (LLY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.8% / 30% | 0.8% / 30% | 2.3% / 30% | 6.08% / 5% | ✗ NOT HALAL |
| DJIM | 4.8% / 33% | 0.8% / 33% | 2.3% / 33% | 6.08% / 5% | ✗ NOT HALAL |
| MSCI | 37.8% / 33% | 6.5% / 33% | 17.9% / 33% | 6.08% / 5% | ✗ NOT HALAL |
| S&P | 4.8% / 33% | 0.8% / 33% | 2.3% / 33% | 6.08% / 5% | ✗ NOT HALAL |
| FTSE | 37.8% / 33% | 6.5% / 33% | 17.9% / 50% | 6.08% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 83.0% | |
| Operating Margin | 44.9% | |
| Net Margin | 31.7% | |
| Return on Equity (ROE) | 101.2% | |
| Return on Assets (ROA) | 19.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $16.8B |
| Free Cash Flow | $6.0B |
| Total Debt | $42.5B |
| Debt-to-Equity | 165.3 |
| Current Ratio | 1.6 |
| Total Assets | $112.5B |
Price & Trading
| Last Close | $897.00 |
| 50-Day MA | $1,007.23 |
| 200-Day MA | $895.68 |
| Avg Volume | 3.1M |
| Beta | 0.4 |
|
52-Week Range
$623.78
| |
About ELI LILLY & Co (LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ELI LILLY & Co (LLY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ELI LILLY & Co is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ELI LILLY & Co's debt ratio?
ELI LILLY & Co's debt ratio is 4.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 37.8%.
What are ELI LILLY & Co's key financial metrics?
ELI LILLY & Co has a market capitalization of $786.0B, trailing P/E ratio of 38.3, and revenue of $65.2B. The company maintains a gross margin of 83.0% and a net margin of 31.7%. Return on equity stands at 101.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.